Fibroblast Growth Factor Receptor (FGFR) Signaling Pathway in Tumor
Holzmann, Klaus
Fibroblast Growth Factor Receptor (FGFR) Signaling Pathway in Tumor - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020 - 1 electronic resource (276 p.)
Open Access
Fibroblast growth factor (FGF) signal transmission has an essential function in embryonic development and tissue repair, and is dysregulated in the vast majority of malignancies studied. The FGF signaling in the tumor cells is usually increased by autocrine and paracrine mechanisms and gives them a high growth potential, resistance to apoptosis, neoangiogenesis and metastasis, all essential parameters relevant for tumor progression. This makes FGFs, and their tyrosine kinase receptors FGFRs, valuable targets for therapeutic interventions. This book is a collection of 15 recent articles—both original work and reviews—that summarize the current research state effectively. The content covers FGF signaling aspects in gastric, skin, liver, esophageal cancer, melanoma, mesothelioma and glioblastoma, including one article that addresses the role of FGF in the tumor-microenvironment cross-talk. Several reports describe the development of compounds targeting FGFRs, their structure and interaction with the receptor molecules, and their effectivity in preclinical and clinical testing. In summary, the papers demonstrate the complexity of the topic, with various FGF ligands and receptors involved and the need for further research. They also present results that fuel hope that targeting cancer with dysfunctional FGF signaling can become a realistic treatment option.
Creative Commons
English
books978-3-03936-785-6 9783039367849 9783039367856
10.3390/books978-3-03936-785-6 doi
Medicine
FGFR4 FGF19 gene regulation cancer signaling anticancer FRS2 FGFR NVP-BGJ398 LY2874455 sarcoma cancer-associated fibroblasts GPER breast cancer estrogen FGFR1 FGF2 optogenetics ERK AKT receptor kinase neurite outgrowth HEK293 PC12 fibroblast growth factor receptors signaling receptor cross-talk coreceptor membrane proteins FGFR2 ERK1/2 phosphorylation serine negative feedback loop cancer prognosis HCC inhibitors FGF fibroblast growth factor autocrine signaling skin melanoma squamous and basal cell carcinoma seborrheic keratosis targeted therapy resistance structure kinase inhibitor gastric cancer monoclonal antibody small molecule FGFR2c autophagy keratinocyte MTOR JNK1 review malignant glioma brain cancer astrocytoma Sprouty proteins FGF-mediated signaling tumor suppressor tumor promoter malignant pleural mesothelioma overall survival immunohistochemistry infigratinib sensitivity FGF8 FGF18 adenocarcinoma of the esophagogastric junction neoadjuvant therapy n/a
Fibroblast Growth Factor Receptor (FGFR) Signaling Pathway in Tumor - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020 - 1 electronic resource (276 p.)
Open Access
Fibroblast growth factor (FGF) signal transmission has an essential function in embryonic development and tissue repair, and is dysregulated in the vast majority of malignancies studied. The FGF signaling in the tumor cells is usually increased by autocrine and paracrine mechanisms and gives them a high growth potential, resistance to apoptosis, neoangiogenesis and metastasis, all essential parameters relevant for tumor progression. This makes FGFs, and their tyrosine kinase receptors FGFRs, valuable targets for therapeutic interventions. This book is a collection of 15 recent articles—both original work and reviews—that summarize the current research state effectively. The content covers FGF signaling aspects in gastric, skin, liver, esophageal cancer, melanoma, mesothelioma and glioblastoma, including one article that addresses the role of FGF in the tumor-microenvironment cross-talk. Several reports describe the development of compounds targeting FGFRs, their structure and interaction with the receptor molecules, and their effectivity in preclinical and clinical testing. In summary, the papers demonstrate the complexity of the topic, with various FGF ligands and receptors involved and the need for further research. They also present results that fuel hope that targeting cancer with dysfunctional FGF signaling can become a realistic treatment option.
Creative Commons
English
books978-3-03936-785-6 9783039367849 9783039367856
10.3390/books978-3-03936-785-6 doi
Medicine
FGFR4 FGF19 gene regulation cancer signaling anticancer FRS2 FGFR NVP-BGJ398 LY2874455 sarcoma cancer-associated fibroblasts GPER breast cancer estrogen FGFR1 FGF2 optogenetics ERK AKT receptor kinase neurite outgrowth HEK293 PC12 fibroblast growth factor receptors signaling receptor cross-talk coreceptor membrane proteins FGFR2 ERK1/2 phosphorylation serine negative feedback loop cancer prognosis HCC inhibitors FGF fibroblast growth factor autocrine signaling skin melanoma squamous and basal cell carcinoma seborrheic keratosis targeted therapy resistance structure kinase inhibitor gastric cancer monoclonal antibody small molecule FGFR2c autophagy keratinocyte MTOR JNK1 review malignant glioma brain cancer astrocytoma Sprouty proteins FGF-mediated signaling tumor suppressor tumor promoter malignant pleural mesothelioma overall survival immunohistochemistry infigratinib sensitivity FGF8 FGF18 adenocarcinoma of the esophagogastric junction neoadjuvant therapy n/a